The amount of academic and early-stage biotech research in cell and gene therapy has skyrocketed over the last few years. However, manufacturing technology for these therapies is largely still at the first-generation stage, stemming from the early academic, without adequate technology solutions available. What are the maturation and roadmap choices made for cell and gene therapy assets? What are the pharma companies’ strategies when sourcing those technologies? Is the pace of deal-making in cell and gene therapy faster and occurring earlier in the drug development process?